Baxter International Again Slashes FY22 Outlook - Update

RTTNews | hace 1209
Baxter International Again Slashes FY22 Outlook - Update

(RTTNews) - While reporting financial results for the second quarter on Thursday, health care company Baxter International Inc. (BAX) again lowered its earnings, adjusted earnings and sales growth for the full-year 2022. The company also provided outlook for the third quarter.

For fiscal 2022, the company now projects earnings in a range of $1.82 to $1.92 per share and adjusted earnings in a range of $3.60 to $3.70 per share on sales growth in the high-teens on a reported basis, in the mid-20s on a constant currency basis and 2 to 3 percent on an operational basis.

Previously, the company expected earnings in a range of $2.35 to $2.43 per share and adjusted earnings in a range of $4.12 to $4.20 per share on sales growth of 23 to 24 percent on a reported basis and 25 to 26 percent on a constant currency basis and about 3 percent on an operational basis.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $4.13 per share on sales growth of 23.2 percent to $15.75 billion for the year. Analysts' estimates typically exclude special items.

For the third quarter, the company anticipates earnings in a range of $0.46 to $0.50 per share and adjusted earnings in a range of $0.79 to $0.83 per share on sales growth in the high-teens on a reported basis, in the mid-20s on a constant currency basis and in the low single-digit on an operational basis.

The Street is looking for earnings of 1.10 per share on revenue growth of 24.6 percent to $4.02 billion for the quarter.

read more
Baxter International Boosts FY24 Outlook - Update

Baxter International Boosts FY24 Outlook - Update

While reporting financial results for the second quarter on Tuesday, health care company Baxter International Inc. (BAX) raised its earnings, adjusted earnings and sales growth guidance for the full-year 2024. The company also provided outlook for the third quarter.
RTTNews | hace 469
Baxter Int'l Launches PERCLOT Absorbable Hemostatic Powder In The US

Baxter Int'l Launches PERCLOT Absorbable Hemostatic Powder In The US

Baxter International Inc. (BAX) announced Monday the launch of PERCLOT Absorbable Hemostatic Powder in the U.S. PERCLOT is a passive, absorbable hemostatic powder that is ready to use and designed for patients with intact coagulation to address mild bleeding.
RTTNews | hace 848
Baxter International Q1 Results Top Estimates; Boosts FY23 Adj. EPS Outlook

Baxter International Q1 Results Top Estimates; Boosts FY23 Adj. EPS Outlook

Health care company Baxter International Inc. (BAX) reported Thursday that net income attributable to Baxter for the first quarter declined to $44 million or $0.09 per share from $71 million or $0.14 per share in the prior-year quarter. Excluding items, adjusted earnings for the quarter were $0.59 per share, compared to $0.93 per share in the year-ago quarter.
RTTNews | hace 936
Baxter Int'l Announces US Launch Of ZOSYN Premix

Baxter Int'l Announces US Launch Of ZOSYN Premix

Medtech firm Baxter International Inc. (BAX) announced Tuesday the U.S. launch of ZOSYN (piperacillin and tazobactam) Injection. Zosyn premix is indicated for the treatment of multiple infections caused by susceptible bacteria and is available in Baxter's proprietary single-dose Galaxy containers.
RTTNews | hace 959
Baxter International Guides Q1, FY23 Adj. EPS Well Below Estimates; To Cut 5% Jobs - Update

Baxter International Guides Q1, FY23 Adj. EPS Well Below Estimates; To Cut 5% Jobs - Update

While reporting financial results for the fourth quarter on Thursday, health care company Baxter International Inc. (BAX) initiated earnings, adjusted earnings and sales growth guidance for the first quarter and for the full-year 2023. The company said the guidance for 2023 reflects a challenging first half of the year due to increased cost of sales resulting from elevated costs of inventory produced in the second half of 2022, reflecting the significant inflationary pressures the company experienced, that will impact earnings when the related inventory is sold in 2023. Baxter expects the impact from these inflationary pressures on its earnings to begin to ease in the second half of the year.
RTTNews | hace 1013
CAC 40 Extends Recent Losses As Stocks Tumble On Economic Worries

CAC 40 Extends Recent Losses As Stocks Tumble On Economic Worries

French stocks are down sharply in negative territory on Tuesday, extending recent losses, amid lingering worries about high tech valuations, and continued uncertainty about interest rate moves of the Federal Reserve. The mood is extremely cautious with investors awaiting AI major Nvidia's updates due on Wednesday, and some crucial U.S. economic data for directional clues.
RTTNews | hace 1h 14min
DAX Down More Than 1% Despite Paring Some Early Losses

DAX Down More Than 1% Despite Paring Some Early Losses

German stock market's benchmark index DAX is sliding for a fourth straight session, falling more than 1% on Tuesday, amid rising concerns about high valuations of Artificial Intelligence-related stocks, and uncertainty surrounding the upcoming policy moves of the Federal Reserve due to a lack of some crucial macro economic data.
RTTNews | hace 1h 28min